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African horse sickness is a severe, often fatal, arboviral disease of equids. The control of African horse sick-
ness virus (AHSV) in endemic countries is based currently on the use of live attenuated vaccines despite
some biosafety concerns derived from its biological properties. Thus, experimental vaccination platforms
have been developed over the years in order to avoid the biosafety concerns associated with the use of
attenuated vaccines.
Various studies showed that baculovirus-expressed AHSV-VP2 or modified Vaccinia Ankara virus
expressing AHSV-VP2 (MVA-VP2) induced virus neutralising antibodies and protective immunity in small
animals and horses.
AHSV is an antigenically diverse pathogen and immunity against AHS is serotype-specific. Therefore,
AHS vaccines for use in endemic countries need to induce an immune response capable of protecting
against all existing serotypes. For this reason, current live attenuated vaccines are administered as poly-
valent preparations comprising combinations of AHSV attenuated strains of different serotypes.
Previous studies have shown that it is possible to induce cross-reactive virus neutralising antibodies
against different serotypes of AHSV by using polyvalent vaccines comprising combinations of either dif-
ferent serotype-specific VP2 proteins, or MVA-VP2 viruses. However, these strategies could be difficult to
implement if induction of protective immunity is highly dependent on using a two-dose vaccination
regime for each serotype the vaccine intends to protect against.
In our study,wehave tested the protective capacity ofMVA-VP2 and baculovirus-expressed VP2 vaccines
when a single dose was used. Groups of interferon alpha receptor knock-out mice were inoculated with
either MVA-VP2 or baculovirus-expressed VP2 vaccines using one dose or the standard two-dose vaccina-
tion regime. After vaccination, all four vaccinated groupswere challengedwithAHSVandclinical responses,
lethality and viraemia compared between the groups. Our results show that complete clinical protection
was achieved after a single vaccination with either MVA-VP2 or baculovirus sub-unit VP2 vaccines.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction is not enveloped and its icosahedral capsid is formed by three con-African horse sickness (AHS) is a viral disease of Equidae trans-
mitted by haematophagus insects of the genus Culicoides. The
disease, which in horses is extremely severe and often fatal, is
caused by African horse sickness virus (AHSV), a member of the
genus Orbivirus, family Reoviridae, closely related to bluetongue
virus (BTV). AHSV is a spherical virion of 55–70 nm in diameter,centric protein layers. The capsid encloses the 10 double-stranded
RNA segments of the genome and the virus replication complex
formed by VP1, VP4 and VP6, which are encoded by genome seg-
ments 1, 4 and 9 respectively [1,2]. The inner capsid protein VP3,
encoded by segment 3, forms the icosahedral scaffold for the outer
core VP7 protein. The outer capsid layer is formed by two major
structural proteins, VP2 and VP5 (encoded by segments 2 and 6
respectively), involved in cell attachment and entry. VP2 is the
most variable antigen of AHSV, determines serotype formation
[3] and contains most of the virus neutralising antibody (VNAb)
epitopes identified so far [3–5].
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plays a critical role. Live attenuatedAHS vaccines have been in use in
Africa for almost 100 years and are the only ones currently licensed
[6–8]. This type of vaccines is not regarded as entirely safe because
of the capacity of vaccine viruses to revert to virulence, their ability
to exchange genome segments with field strains, and for their ter-
atogenicity. Recent studies indicate that outbreaks of AHS occurring
in the Western Cape Province of South Africa between 2004 and
2014 resulted from re-assortment events involving vaccine strains
of serotype1 [9]. The drawbacks of live attenuated vaccines together
with their inability to discriminate vaccinated from infected ani-
mals in vaccinated horse populations make their use highly debat-
able, especially in non-endemic countries.
Over the last 30 years much attention has been given to the
development of safer alternative AHS vaccines and a number of dif-
ferent approaches have been explored. Some of these approaches
exploit the power of reverse genetics [10] to generate gene defec-
tive (yet biologically active) AHSV with impaired replication capac-
ity [11–15].
Other strategies are based on VP2 and/or VP5, which bear virus
neutralizing epitopes, and include baculovirus-expressed VP2 sub-
unit vaccines [16–18] or recombinant viral vector vaccines
(Canarypox or Modified Vaccinia Ankara [MVA]) expressing these
antigens [19–25]. In the case of baculovirus VP2 vaccines, the pro-
tein is produced in vitro and then administered as a cell lysate with
an adjuvant. Canarypox VP2/VP5 viruses are formulated with a
Carbomer adjuvant and immunogenicity is expected to depend
on expression of VP2/VP5 from within cells of the vaccinated host
after inoculation. The immunogenicity of experimental MVA-VP2
vaccines, rely on the expression of VP2 from host cells after vacci-
nation and also on presence of pre-formed VP2 in the vaccine
inoculum [19]. All these vaccines have been shown to be protective
and rely on the efficient induction of virus neutralizing antibodies
(VNAb), which typically occur after a primary course of two vacci-
nations. However, it is not known what levels of immunity would
be obtained after a single dose. The availability of this information
would be important for the development of polyvalent vaccines for
AHS based on these strategies as it would enable to reduce the
costs of production and the number of vaccine doses to be given.
Indeed, AHS immunity is serotype specific and vaccines for
AHSV need to induce protective immunity across all nine serotypes,
especially if they are to be used in endemic countries. For this rea-
son, live attenuated vaccines are formulated as polyvalent vaccines
comprising combinations of different strains representing different
serotypes [26]. Thus, a typical vaccination course comprises two
inoculations: one dose containing serotypes 1, 3 and 4, followed
by a second dose containing serotypes 2, 6, 7 and 8 administered
one month later. Generating polyvalent AHSV vaccines using
recombinant baculovirus-expressed VP2, MVA-VP2 or Canarypox
VP2/VP5 would require combining single serotype-specific con-
structs and some studies indicate that this is possible [16,20]. Such
polyvalent vaccination strategies would be easier to implement if
protection could be achieved after one vaccination dose.
In this study, we examined, in a vaccination and challenge
experiment in a mouse model, the levels of protection conferred
by MVA-VP2 and baculovirus-expressed VP2 vaccines upon a sin-
gle inoculation.
2. Materials and methods
2.1. Baculovirus expressed VP2 vaccines
2.1.1. Cells
Insect cell lines Sf9 and Sf21 from Spodoptera frugiperda and
TnHi5 from Trichoplusia ni, were cultured at 28 C. Sf9 and TnHi5
cells were maintained in ESF 921 serum-free medium (ExpressionSystems) and Sf21 cells were maintained in TC100 (Gibco) medium
supplemented with 10% (v/v) foetal bovine serum (FBS) [27].
2.1.2. Preparation of recombinant baculovirus expressing AHSV4 VP2
protein
Nucleotide sequences encoding AHSV4 VP2 were PCR-amplified
from the template vector pSC11-AHSV-4-VP2 [24] using gene-
specific primers. A polyhistidine tag (6His) coding sequence
was added to the 50 terminus of the VP2 sequence during the
PCR amplification. The PCR product, VP2HIS/N, was sub-cloned into
the pGEM-T Easy vector prior to cloning into the pOET-1 bac-
ulovirus transfer vector (Oxford Expression Technologies Ltd
[OET]) using NotI restriction sites to generate the recombinant vec-
tor pOET1_VP2HIS/N.
Recombinant baculovirus expressing his-tagged AHSV4-VP2
was generated using the flashBACTM system following the supplier’s
protocol (OET). Briefly, Sf9 cells (0.7  106 cells/dish) were co-
transfected with the flashBACULTRA virus DNA (100 ng) and the
pOET1_VP2HIS/N transfer vector (500 ng) using a liposome-
mediated transfection method (LipofectinTM, Invitrogen). Following
5 days of incubation at 28 C, culture medium containing the
recombinant virus, AcVP2HIS/N, was harvested (P0 virus seed stock).
Subsequently, a 50 ml P1 virus stock was amplified in Sf9 cells
maintained in shaker cultures (2  106 cells/ml) during 5-day incu-
bation at 28 C. Virus stocks were titrated using a QPCR-based titra-
tion system following the supplier’s protocol (baculoQUANTTM, OET)
[28]. Subsequent titrations were carried out using the standard pla-
que assay system in Sf21 insect cells as described previously [27].
2.1.3. Preparation of purified VP2 protein
TnHi5 insect cells seeded in large tissue culture dishes
(1.7  107 cells/dish, 38 dishes in total) were infected with AcV-
P2HIS/N using a multiplicity of infection (moi) of 5. After 72 h incu-
bation at 28 C, the infected cells were harvested by centrifugation
at 4000 rpm for 15 min at 4 C. The cell pellets were resuspended
in lysis buffer (10 mM Tris-HCL, pH 8.0, 0.15 M NaCl, 1 mM EDTA
and 1% (v/v) NP-40 supplemented with Protease inhibitor cocktail
(Calbiochem)) and incubated on ice for 1–2 h. Following cell lysis,
the medium was clarified by centrifuging at 20,000 rpm for 20 min
at 4 C. 0.15 M NaCl and 10 mM imidazole were added to the clar-
ified medium, which was then incubated with nickel-coated
sepharose beads (GE Healthcare) on a rotating platform for 2 h at
4 C. After the incubation, the beads were transferred onto Proteus
1-step batch midi spin columns (Generon) and washed three times
using Buffer A (20 mM Tris-HCl, pH 8.0, 0.3 M NaCl, 10 mM imida-
zole). His-tagged proteins were then eluted from the beads with
Buffer B (300 mM imidazole, 20 mM Tris-HCl, pH 8.0 and 0.3 M
NaCl) and stored at 4 C until used.
Samples from the purification fractions were mixed with 1/5th
volume of 6X Laemmli SDS-PAGE loading buffer (250 mM Tris-HCl
pH 6.8, 10% SDS, 50% (v/v) glycerol, 0.05–0.5% bromophenol blue
and 25% (v/v) b-mercaptoethanol) and analysed with SDS-PAGE
followed by western blotting and Coomassie staining. Total protein
concentration of the eluate samples was estimated with BCA pro-
tein assay using the standard micro-scale assay format following
the supplier’s instructions (Novagen) and VP2 protein concentra-
tion was determined by band densitometry from the Coomassie
stained gels.
2.2. MVA-VP2 vaccines
Vero cells (ATCC, Cat. No. CCL-81) and Chicken embryo fibrob-
last (DF-1) (ATCC, Cat. No. CRL-12203) were grown in high glucose
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
2 mM glutamine, penicillin (100 units/ml), streptomycin (100 mg/
ml) and 10% foetal calf serum (FCS). MVA-VP2, expressing
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VP2 vaccine virus was bulked up for this study in DF-1 cells and
subsequently used as a cell lysate. Virus stocks were generated
by infection of sub confluent cells using a multiplicity of infection
(MOI) of 0.1. When a total cytopathic effect (CPE) was visible, the
cells and supernatants were harvested and centrifuged. The virus
was released from the cells by three freeze/thaw cycles, sonication
and then titrated by plaque assay.
2.3. Western blot
Immunoblotting was performed as described previously [24].
Samples were mixed 1:5 with 5 Laemmli sample buffer and
10 mL were loaded in each well of polyacrylamide gels. Three
immunogenic AHSV-4 VP2-derived KLH-conjugated peptides
(NH2-KKKEEGEDDTARQEIRKAWC-COOH; NH2-NKGKWKEHIKEVT
EKLKKA-COOH; NH2-DMNEKQKPYFEFEYDDFKPC-COOH) were
selected to obtain a VP2-specific rabbit polyclonal antibody from
a commercial source (GenScript). This antibody was used at a
1:1000 dilution. As a secondary antibody, a horseraddish
peroxidase-labelled goat anti-rabbit IgG (Sigma) was used at a
dilution of 1:50,000. Alternatively, detection of VP2 antigen by
Western blotting was performed with AHSV-4 VP2-specific mono-
clonal antibodies (MAb) 8BG9 and 8DB11 (INGENASA, Madrid,
Spain), used at a 1:500 dilution, and a horseraddish peroxidase
labelled goat anti-mouse IgG (Jackson Immuno Research) as a sec-
ondary antibody at a 1:50000 dilution.
2.4. Mice
Seven-week-old, female, Type I interferon receptor KO A129
IFNAR (/) mice were purchased from B&K Universal. The ani-
mals were rested for about a week before the experiments were
performed in the animal facilities of the Centro de Investigación
en Sanidad Animal (INIA-CISA). All protocols for animal use were
approved by the Ethical Committee of the Centre for Animal Health
Research (CISA-INIA) (Permit number: PROEX 039/15) in strict
accordance with the Spanish National Royal Decree (RD1201/
2005), EU guidelines 2010/63/UE about protection of animals used
for experimentation and other scientific purposes, and the Spanish
Animal Welfare Act 32/2007.
2.5. Vaccination of animals.
Five groups of IFNAR –\– mice (n = 6) were used in the study
(Table 1). Groups 1 and 2 were vaccinated with one or two doses
of MVA-VP2 at 107 pfu/mouse respectively. Groups 3 and 4 were
vaccinated with one or two doses of Alum adjuvanted VP2HIS/N at
10 mg per mouse. Baculovirus-expressed VP2 in saline was added
to Alum at a 1:1 ratio and administered to mice. Group 5 was
not vaccinated and used as control.
2.6. Plaque reduction neutralization test (PRNT)
Serial dilutions of mouse sera were incubated with 100 pfu of
AHSV-4 for 1 h at 37 C. Then, samples were inoculated into oneTable 1
Vaccination groups and dosage.
Group Vaccine Dose Number of doses Days of vaccination
1 MVA-VP2 107 pfu/ml 1 Day 0
2 MVA-VP2 107 pfu/ml 2 Days 0 and 21
3 VP2 10 mg 1 Day 0
4 VP2 10 mg 2 Days 0 and 21
5 PBS 2 Days 0 and 21well each of 12-well plates containing confluent monolayers of
Vero cells. Following incubation for 1 h at 37 C in 5% CO2 an agar
overlay (DMEM, 10% FBS, 0.4% agar) was added and plates incu-
bated further for 5 days at 37 C in 5% CO2. Plaques were visualized
with a counter-stain solution (2% crystal violet, 10% formaldehyde,
PBS). PRNT titre was calculated as the reciprocal (log10) of the high-
est dilution of serum that neutralised 50% of the control virus
input.2.7. Detection of antibodies against VP2 by ELISA
MaxiSorp plates (Nunc, USA) were coated with VP2 purified
baculovirus expressed proteins (164 ng per well) and incubated
overnight at 4 C. Plates were saturated with blocking buffer
(PBS-0.05% Tween 20 and 5% skim milk). The animal sera diluted
in blocking buffer were added and incubated for 1 h at 37 C. After
three washes in PBS-0.05% Tween 20, plates were incubated for 1 h
at 37 C with an anti-mouse-HRP secondary antibody (Biorad, USA)
at a 1:2000 dilution in blocking buffer. Finally, after three washes
in PBS-0.05% Tween 20, the reaction was developed with substrate
solution tetramethylbencidine liquidsupersensitive (TMB) (Sigma)
and stopped by adding 50 ml of 3 N H2SO4. Results were expressed
as optical densities (ODs) measured at 450 nm. Background OD
values were obtained from wells containing blocking buffer with-
out serum samples. This background OD was subtracted from the
OD measurements of the sample wells.2.8. Challenge with AHSV
The AHSV-4 virus stock used for challenge and for virus neutral-
isation tests has been previously described [23]. This was derived
from a Spanish isolate of AHSV (Madrid-87), which was passaged
twice in mouse brain and three times in BHK-21 cells before stocks
for this study were prepared. These were grown in Vero cells and
used to challenge the mice by sub-cutaneous injection of 106 pfu/
mouse 5 weeks after all vaccinated mice received the first vaccina-
tion. Animals were monitored twice a day after challenge and clin-
ical signs recorded. Mice were sampled at regular intervals for
analysis of virus load in blood.2.9. Clinical signs and viraemia
Clinical scoring was performed as described previously [29].
Mice were humanely euthanized when they showed severe clinical
signs (weight loss, dehydration, frequent hunching, severe con-
junctivitis or any other condition that prevented food or water
intake). Whole-EDTA-blood samples were collected from the sub-
mandibular vein at different days post infection to analyse virae-
mia. Blood cells were lysed with water before performing plaque
assays on Vero cells as described previously [23].2.10. Statistical analysis
Differences in antibody levels between groups inoculated with
various AHSV-VP2 vaccines (groups 1 to 4) were determined using
the Sidak-Bonferroni method. Clinical scores in different groups of
mice were compared by Kruskal-Wallis test. Differences between
groups were then explored using Wilcoxon rank-sum tests. Titres
of viraemia were compared using a Kruskal-Wallis test, followed
by Mann-Whitney non-parametric tests to identify differences
between groups at 4 and 7 dpi. Survival data were analysed using
a log rank test with mice grouped by immunisation strategy. A sig-
nificance level of P = 0.05 was used in all analyses.
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3.1. Production and optimizing the yield of baculovirus expressed
AHSV4-VP2
The first stage for preparing VP2 based vaccines was the pro-
duction and purification of the VP2 protein in the baculovirus sys-
tem. Preliminary experiments showed that expression levels of
AcVP2HIS/N in Sf9 cells were variable and often the protein was
not detectable by SDS-PAGE and Coomassie blue staining. There-VP2-sHistidine-specific antibody 
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Fig. 1B. Analysis of VP2HIS/N purification. TnHi5 cells (1.7  107 cells/dish) were infected
4000 rpm, 15 min at 4 C and VP2HIS/N was purified using nickel-coated sepharose beads.
analysed by SDS-PAGE, followed by western blotting (top) and Coomassie Brilliant blue R
protein analysis. Only Eluate 1 was used in the vaccine preparation. (For interpretation
version of this article.)fore, we also explored the potential of TnHi5 cells to support the
production of VP2 following infection with AcVP2HIS/N. Thus, Sf9
and TnHi5 cells were infected with AcVP2HIS/N using a multiplicity
of infection (MOI) of 5 pfu/cell and the expression levels of AHSV
VP2 was analyzed after harvesting the cells at 72 h post-infection.
Recombinant VP2 was clearly detected from crude AcVP2HIS/N
infected TnHi5 cell lysates using both anti-Histidine and anti-VP2
specific antibodies (Fig. 1A). In contrast, VP2 could not be detected,
with either antibody, in crude AcVP2HIS/N infected Sf9 cell lysates in
the immuno-blots.pecific antibody (Rabbit 
B, 1:200)
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/dish) were infected with AcVP2HIS/N using 5 moi. The cells were harvested at 72hpi
E, followed by western blotting using histidine- and VP2-specific antibodies.
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with AcVP2HIS/N using 5 moi. The cells were harvested at 72 hpi by centrifugation at
Purified protein was collected in 8x1ml eluate fractions. Purification fractions were
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Fig. 1C. Antigenic reactivity of purified VP2HIS/N to AHSV4-specific monoclonal antibodies. Purified VP2HIS/N was analysed by SDS-PAGE followed by western blotting using
two monoclonal (8BG9 and 8DB11) and a polyclonal (R190) AHSV4-VP2 specific-antibodies.
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TniHi5 cells, was performed by affinity chromatography. Although
affinity-purified VP2 could be detected by Western blotting in both
Sf9 and in TnHi5 cells, expression levels in Sf9 were not sufficiently
high for detection by Coomassie blue staining in SDS-PAGE gels
(data not shown). In contrast, VP2 was expressed abundantly in
TnHi5 cells as evidenced by the detection of protein bands of
approximately 124 kDa in several eluate fractions byWestern blot-
ting and Coomassie blue staining (Fig. 1B). Consequently, TnHi5
cells were used for the preparation of the VP2 vaccine stocks for
this vaccination study.
The total protein concentration, measured by BCA protein assay,
in individual eluate samples collected from AcVP2HIS/N infected
TnHi5 cells (6.5  108 cells in 950 ml) was estimated to be
318 mg from eluate 1 and 179 mg from eluate 2. Only the first eluate
was used for vaccine preparation.
The antigenicity of purified VP2 was further confirmed by
immunoblotting with VP2-specific MAb in addition to VP2-
specific rabbit polyclonal antiserum. Both MAbs reacted with the
purified protein (Fig. 1C).3.2. Antibody responses following vaccination
All vaccinated mice developed VNAb against AHSV following
vaccination (Table 2). One animal of group 2 died at day 15 without
showing clinical signs the previous days; therefore it was consid-
ered that this death was not related to the vaccination. Pools of
sera from each group were analysed in duplicate. The serum VNAb
titres before challenge (day 35) of groups 2 and 4, which received
two vaccine doses, were higher (mean PRNT 2.34 and 1.87 respec-
tively) than those of groups 1 and 3 (mean PRNT 1.69 and 1.39
respectively), which received just one vaccination dose. There wereTable 2
Results of PRNT test and ELISA of serum samples collected from mice groups 1–4 on
day 35 post-vaccination.
Group Mean Log10 PRNT50 ± SD Mean OD ELISA VP2 ± SD
1 1.695 ± 0.049 0.99 ± 0.27
2 2.34 ± 0.071 1.70 ± 0.18
3 1.365 ± 0.177 0.42 ± 0.27
4 1.869 ± 0.015 1.65 ± 0.7statistically significant differences in VNAb titres among groups
(P < 0.05).
The presence in serum of specific antibodies to VP2 was also
analysed before challenge by indirect
ELISA using individual samples. Responses measured by ELISA
indicated that, as expected, the OD values of the negative control
were very low (mean OD 0.044). Results of the vaccinated groups
were consistent with VNAb data, indicating that higher antibody
responses were obtained for groups 2 and 4 (mean OD 1.7 and
1.65 respectively) than for groups 1 and 3 (mean OD 0.99 and
0.42 respectively). In this case, there were significant differences
(P = 0.005) between groups 1 (MVA-VP2) and group 3 (baculovirus
expressed VP2 vaccine) when one dose was used. In contrast, there
was not a statistical difference between groups 2 and 4, indicating
that both vaccines were effective at inducing VP2 antibodies in
these vaccine groups. However, MVA-VP2 vaccines induced higher
titres than baculovirus-expressed VP2 vaccines. As expected, there
were significant differences between animals vaccinated with one
or two doses, i.e. between groups 1 and 2 (P = 0.004); and between
3 and 4 (P = 0.004).3.3. Challenge
Three weeks following the last vaccination all mice, including
the negative control group, were challenged with AHSV-4 and pro-
tective efficacy was assessed. None of the non-vaccinated controls
survive the challenge. In contrast, all vaccinated mice survived the
infection. Clinical signs were significantly reduced in comparison
with the unvaccinated controls (group 5). Clinical signs in group
5 started on day 3 post-infection and reached the humane end-
point between days 4 and 9 post-challenge (Fig. 2). These signs
included dehydration, ocular discharges, periorbital swelling and
hunching. In contrast, mice from all other groups survived the
challenge and developed no clinical signs (except one mouse in
group 3). Survival was significantly (P < 0.0001) lower in unvacci-
nated mice compared to all other groups.
Clinical scores were negative for mice receiving one or two
doses of MVA-VP2 and for mice receiving two doses of baculovirus
expressed VP2 vaccine (group 4). Clinical signs were highly
reduced in animals vaccinated with one dose of the baculovirus
expressed VP2 as only one mouse of group 3 displayed mild clinical
signs (Fig. 3). The average clinical score index for group 5 was
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Fig. 3. Clinical score index of groups of mice after infection with AHSV-4. A clinical
scoring system was used whereby each animal received a clinical score value per
day. The value used for analysis was the individual mean clinical score for the study
period (sum of daily scores of each animal/number of days). Standard deviations are
shown as error bars.
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Fig. 4. Titres of AHSV-4 recovered in blood of immunized and non-immunized
IFNAR (–/–) mice after challenge. Analysis of infectious virus was performed at 0, 4,
7, 10 and 14 dpi by plaque assay. Each point represents the mean value of the viral
titre of six animals, and standard deviations are shown as error bars.
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Fig. 2. Survival rates of immunized and non-immunized IFNAR (–/–) mice after
inoculation with AHSV-4. Groups of mice 1 to 4 (n = 6) were immunized with MVA-
VP2 or baculovirus VP2 protein after a single or double vaccination. Non-
immunized group 5 was inoculated with PBS and used as a control. At day 35 all
mice were subcutaneously inoculated with 106 PFUs of AHSV-4. The mice were
observed every 24 h for 14 days.
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recorded for the other vaccinated groups (P = 0.03), as expected.
The clinical protection afforded by a single dose of either vaccine
was evident and there were no statistical differences between
the levels of protection observed for vaccinated groups despite
some subtle clinical signs were observed in group 3.
A statistically significant reduction of viraemia (P < 0.05) was
observed in all vaccine groups relative to the unvaccinated controls.
Thus, AHSV concentration in blood was below the threshold of
detection of the assay in animals from Group 2 during the whole
study period (Fig. 4). Some individuals of the other vaccinated
groups developed low levels of viraemia in some animals: three
in group 1; one in group 4; and all animals in group 3. However, vir-
aemia was cleared by day 7 p.i. in groups 1 and 4, and by day 10 p.i.
in group 3. The levels of viraemia on days 4 and 7 p.i. were signifi-
cantly lower (P = 0.002 and P = 0.01 respectively) in vaccinated
groups relative to the unvaccinated group. High viral loads were
detected in unvaccinatedmice, reaching maximum values between
days 4 and 7post-challenge. The average viral titre in group 5 was
1587.5 pfu /ml at day 4 p.i. and 450 pfu/ml at day 7 p.i.All these results indicated that vaccination with MVA-VP2 or
baculovirus-expressed VP2 induced protective immunity against
AHSV, even after using a single vaccine dose. This protection was
characterised by a complete prevention of lethality of AHSV infec-
tion in all vaccinated groups, an absence of viraemia in group 2 and
a significant reduction of clinical signs and viraemia in groups 1, 3
and 4 relative to the control group. The level of protection observed
in the different groups of vaccinated mice seems to correlate with
antibody response against AHSV (Table 3). Viraemia, viral load,
lethality and clinical scores are directly proportional to the VNAb
pre-challenge.4. Discussion
Previous studies in the mouse model with experimental AHSV
MVA-VP2 vaccines indicated that VNAb are an important effector
mechanism of immunity against AHSV [22,29]. Immunogenicity
of live attenuated, inactivated and DISC and DISA vaccines is nor-
mally studied in relation to the levels of VNAb induced in the vac-
cinated animals, although studies in mice and horses indicate that
cell-mediated immunity seems to also play a role in protection
against AHSV [29–31]. To date, no published studies have specifi-
cally established the minimum VNAb titre in serum required to
provide immunity against AHSV in horses. However, the vaccine
manufacturer of the attenuated vaccine relies on the induction of
a titre of 1/16 as minimum requirement for protection in horses
[32] and other data suggest that a titre of 1/64 would confer solid
immunity against AHSV with prevention of clinical signs and virae-
mia also in horses (Baltus Erasmus, personal communication). High
levels of VNAb titres are seldom achieved by a single immunization
with any type of AHSV vaccine. This is the reason why protection
efficacy experiments are rarely performed after a single vaccina-
tion, when VNAb titres are still low.
In this study, we have evaluated, in the IFNAR –/– mouse model,
the protective capacity against virulent AHSV challenge, of recom-
binant MVA-VP2 and baculovirus-expressed VP2 vaccines follow-
ing a single vaccine dose. For this, we have vaccinated groups of
6 mice with either MVA-VP2 or baculovirus-expressed VP2 adju-
vanted vaccines using either one or two doses and challenged
the vaccinates with AHSV. Clinical signs, survival and viraemia
were compared between the vaccinates and a negative control
group of mice which was challenged at the same time of the vac-
cinates. We showed that protection against lethality, clinical signs
and viraemia in all vaccine groups was very high and statistically
significant respect to the control group. As expected, individuals
Table 3
Correlation VNAb with protection.
Level of protection Group Log10 PRNT50* OD ELISA VP2* Clinical protection Viraemia Viral load (pfu/ml)* Survival
High 2 2.34 1.70 5/5 0/0 0 5/5
High/medium 4 1.87 1.65 5/5 1/5 8.33 5/5
High/medium 1 1.69 0.99 5/5 3/5 41.66 5/5
Medium 3 1.36 0.42 4/5 5/5 100 5/5
Low 5 < 0.69 0.044 0/5 5/5 1587.5 0/5
* Mean values of the group.
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receiving just one dose showed high levels of protection in the face
of relatively low serum VNAb titres at the time of challenge.
The results above might suggest that cell mediated immunity
contributed to the protection levels observed in animals vaccinated
with one dose. Indeed, we showed previously that MVA-VP2 vacci-
nes induce cellular immunity and that transferred splenocytes
from vaccinated mice to naïve recipients conferred certain degree
of immunity in the latter [22]. However, it is also possible that
priming the immune system, through MVA-VP2 or baculovirus-
expressed VP2 immunisation, enabled a strong anamnestic VNAb
response upon a second encounter with the VP2 antigen when
the vaccinated mice were challenged with AHSV and that this
was sufficient to prevent clinical signs and lethality in the vacci-
nates. Protective efficacy of one-dose vaccination has also been
proven by other studies that used different vaccine platforms
against various disease targets such as porcine circoviral disease,
PCVD, [33], influenza [33–35], classical swine fever, CSF, [36], Ebola
and Marburg [37].
Achieving protective immunity by a single vaccination could be
amajor step forward in the development of viral vector vaccines for
an antigenically plural pathogen such as AHSV, especially if the vac-
cine is for use in endemic countries where protection against sev-
eral serotypes is required. Recently, Kanai and co-workers
demonstrated the potential to generate polyvalent AHSV vaccines
using baculovirus-expressed AHSV-VP2 in a serological study in
mice [16]. Similarly, previous vaccination studies in ponies byMan-
ning and co-workers, demonstrated that recombinant MVA-VP2
vaccines can potentially be used in polyvalent formulations [20].
Indeed, the latter study showed that simultaneous administration
of two recombinant MVA-VP2 vaccines, each expressing an AHSV
VP2 protein from a different serotype (one from serotype 4 and
another one from serotype 9) followed by a booster vaccination
5 months later with a recombinant MVA-VP2 vaccine specific for
another serotype (AHSV-5), resulted in the induction of antibodies
that neutralized the infectivity of 5 AHSV serotypes. However, the
induction of high VNAb was achieved after 2 vaccine doses. This
requirement would have implications in the design of the vaccina-
tion regime as well as vaccine production costs. Therefore, the pos-
sibility of achieving protection after a single dose of MVA-VP2 or
baculovirus-expressed VP2 vaccination could reduce the number
of doses to be given, facilitate the design of the vaccination regime
and reduce costs of vaccine manufacturing.
In our study, the protection conferred by the baculovirus-
expressed VP2 vaccine was comparable to that of MVA-VP2 vacci-
nes, in particular when two doses of the baculovirus expressed VP2
vaccine were used. This finding is not surprising as other research-
ers previously showed the protective capacity of sub-unit vaccines
based on VP2. However, previous studies with baculovirus-
expressed AHSV-VP2 vaccines used Spodoptera frugiperda cells,
mainly Sf9, as the target host for production of the vaccine
[16,17,38–40]. Some of these studies showed that the production
yields of VP2 from AHSV4 [38] and AHSV5 [39] using Sf9 cells were
low and most of the protein was insoluble. Further analysis carried
out in guinea pigs [39] and horses [17] showed that the generationof VNAb is dependent on the presence of soluble VP2. Production of
VP2 in Sf9 cells was also proven to be difficult in our study. How-
ever, the use of another insect cell line, Trichoplusia ni, (TnHi5) was
shown to increase the production yields of VP2 with recombinant
baculoviruses. The differences in protein expression profiles
between these two cell lines have also been observed in several
other studies, where TnHi5 cells were favoured for the expression
of recombinant proteins and virus-like-particles [41,42]. All previ-
ous baculovirus-based AHSV-VP2 vaccines were formulated from
crude cell lysates or soluble protein extracts [16,17,38–40]. The
presence of molecules other than VP2 in the vaccine would make
it difficult formulating this type of vaccines and assess their
potency in vitro. In our study, the baculovirus-expressed VP2 was
eluted easily from the affinity columns using imidazole, without
using denaturing agents such as Urea or Guanidine Hydrochloride.
Although we have not assessed specifically what proportion of the
protein was insoluble, our data indicate that most of the protein
was indeed soluble. The affinity purification process improves pur-
ity of the vaccine preparation reducing the presence of other mole-
cules in the vaccine’s inoculum. To our knowledge, this is the first
study to show the protective efficacy of histidine-tagged affinity-
purified VP2 in a vaccination-challenge experiment. It is possible
that this technical finding could facilitate the production of this
type of vaccines in an industrial setting.
Overall, the preliminary results from our study show the poten-
tial of generating single-dose AHSV vaccines using baculovirus and
MVA platforms. These findings warrant further investigations
directed at testing the protective efficacy of polyvalent vaccines
based on baculovirus-expressed VP2 and MVA-VP2.Acknowledgements
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